



Artificial Intelligence and Technical Services

CIARA DUFFY

RPS BOARD MEMBER

QP & SPECIALIST PROJECTS NOVARTIS



Agenda

Introduction and Overview

Understanding AI

Machine Learning

Large Language Models

Regulatory Landscape

AI in Practice

Critical Thinking and AI


Conclusion



**KEEP YOUR
EYES PEELED**

**Looks can be deceiving:
Always verify AI**

Career Path



Investigational medicinal products considerations in pediatric clinical drug trials

Mandy Wan^{1,2}, Samantha Carmichael³ and Ciara Duffy⁴

¹Evelina Pharmacy Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom;

²Institute of Pharmaceutical Science, King's College London, London, United Kingdom; ³NHS Greater Glasgow & Clyde, Glasgow, United Kingdom; ⁴Novartis Pharmaceuticals UK Ltd, London, United Kingdom



Clinical Trials
+
Commercial Products
+
Specialist Projects

My AI Journey




**ACT OR BE
ACTED UPON**

What is Artificial Intelligence (AI)?

AI, or Artificial Intelligence, refers to algorithms designed to mimic or simulate human cognitive abilities. This includes information processing, establishing relationships between multiple elements, learning and adapting to new concepts, making decisions, and adjusting to new situations.




Differences Between AI and Automation



AI VS AUTOMATION	AI - ARTIFICIAL INTELLIGENCE	AUTOMATION
Definition	A sector of computer science focused on creating intelligent machines that mimic human intelligence	A technique used to make a system operate automatically to accomplish repetitive tasks based on preset rules and commands
Key Capabilities	Problem-solving, speech recognition, learning, planning	Handles repetitive tasks without human intervention
Learning Ability	Has the ability to adapt and learn from new information	Lacks the ability to learn from processed data
Complexity of Tasks	Can cope with complex tasks involving decision-making or problem-solving	Best suited for straightforward, repetitive tasks
Interaction	Capable of interacting with humans and predicting user needs	Lacks human-like interaction
Data Analysis	Can analyze and interpret large volumes of data	Can process large data but lacks interpretation capability

Differences Between AI and Automation


Automation (Past & Present)



Rule-based image checks (pixels, contrast, thresholds)

Example: Detecting if a vial is empty or misaligned
“If X, then Y — no learning, just rules


Discriminative AI (Now)



Machine learning models trained on “good” vs “defective” vials

Example: CNN classifies particles, cracks, or label defects
Learns from data to classify defects

Generative AI (Emerging)




Generates synthetic defect images to improve training sets


Example: Creating rare defect scenarios for validation
Creates training data, making inspection smarter

AI Terminology

The AI Universe



AI Type	Discriminative (Narrow) AI	Generative AI
Overview	Implements predefined rules and applies machine learning for predictive analytics	Employs deep learning for tasks involving creativity and innovation, generating new, useful data from existing information
Example in Drug Manufacturing	Analyzes historical production data and optimizes assembly line operations, making real-time adjustments to enhance efficiency and reduce waste	Learns from a vast database of chemical reactions and designs and optimizes synthetic routes for drug manufacturing. It proposes the most efficient, cost-effective, and eco-friendly way to synthesize a drug
Key Applications II	Visual inspection, Monitoring, predictive maintenance	Content Generation Automation (Text, Tables), Draft Document generation,



Artificial Intelligence Models - Examples

Model Type	What It Does	Everyday Example
Transformer-based LLM	Learns patterns in language to understand, predict, or generate human-like text	ChatGPT writing emails, Copilot drafting documents
CNN (Convolutional Neural Network)	Recognises patterns in images by scanning for shapes, edges, textures	Google Photos tagging faces, Instagram filters
GNN (Graph Neural Network)	Learns from networks (like social or molecular graphs); considers relationships between items	LinkedIn friend suggestions, fraud detection
Knowledge Graph	Connects pieces of information as relationships in a web of knowledge	Google Search showing “related people” or facts
Reinforcement Learning	Learns by trial and error -rewards success, punishes failure	YouTube recommending videos based on watch behaviour
Collaborative Filtering	Looks at what similar users liked to predict what you’ll like	Spotify suggesting songs, Netflix recommending shows
Recommendation System	Combines filters, behaviour, and rewards to make smart predictions	Amazon suggesting “People who bought this also bought...”

Machine Learning

Machine learning is a subset of artificial intelligence (AI) that involves the development of algorithms and statistical models enabling computers to learn from and make predictions or decisions based on data.



Machine Learning

- **Reinforcement Learning**

Learn to make sequential decisions to maximize rewards

Eg : Chess AI.

- **Unsupervised Learning**

Discover Patterns, relationships or groupings with unlabeled data

Eg: Recommendation system used by websites like Amazon and Netflix.

- **Supervised Learning**


Predicts or Classify based on labeled data

Labeled data with input output pair

Eg:Spam emails

Machine Learning : Neural Networks

Deep neural network



- Neural networks are brain-inspired models that power AI to spot patterns and make decisions from data.
- Deep networks pack many layers and millions of parameters, making them powerful—but hard to explain from input to output.

Large Language Models



ANTHROPIC

- ❑ LLM: A Large Language Model is a type of neural network model that has been trained on a vast amount of text data to understand and generate human language.
- ❑ LLMs can perform a variety of language-related tasks such as text completion, translation, summarization, and question answering.
- ❑ Generative Pre-trained Transformer GPT is a specific implementation of a Large Language Model developed by OpenAI Trained on large text corpora



Limitations and Risks of Large Language Models (LLMs)

Unpredictable Outcomes: Reliance on probability models can produce unexpected results.

Lack of Transparency: Hidden layers in deep neural networks are difficult to interpret.

Dependency on Prompts: Output accuracy is heavily influenced by the quality and clarity of given prompts.


Data Exposure: LLMs require relevant data to generate accurate results; insufficient exposure increases error risk.

Bias Amplification: LLMs can inherit and amplify biases from their training data, potentially causing unfair or discriminatory outcomes.

Overfitting: Excessive fitting to training data may result in poor performance on new, unseen data.



Regulatory Hierarchy



EU Regulatory Landscape

◆ EU AI Act – [Artificial Intelligence Act 2024/1689](#)

Global First

Risk-based approach

Phased implementation;

1 Aug 2024 → Act entered into force.

Feb 2025 → Prohibited AI practices banned (e.g., social scoring, manipulative AI).

Aug 2025 → General Purpose AI / foundation models rules apply (like GPT-style models).

Aug 2026 → High-risk AI rules apply (covers pharma, healthcare, medical devices, critical infrastructure).

Aug 2027 → All provisions fully applicable.

•Key obligations

Governance

- Risk management and quality management systems
- Transparency, logging, and record-keeping

Data & Technical Standards

- Data governance, traceability, bias controls
- Accuracy, robustness, and cybersecurity

Human Oversight

- Human-in-the-loop where required

Model Scope

- GPAI providers: transparency and risk mitigation
- Systemic-risk models: enhanced obligations for very large LLMs

AI Regulation – Rest of the World



United States

- No single federal AI law
- Executive Orders + NIST AI Risk Management Framework (voluntary)
- Sector regulators (FDA, FTC) shaping AI oversight



Canada

- Artificial Intelligence & Data Act (AIDA) tied to Bill C-27



Singapore

- Model AI Governance Framework + AI Verify –practical, non-binding but detailed tools



Japan

- ‘Soft law’ approach
- Interim government response (2024)



China

- Generative AI rules’(Aug 2023) – binding for providers (registration, transparency, content controls)
- Draft AI Law (2024–25) under discussion – full framework likely coming



Japan

- “Soft law’ approach
- Principles & guidelines focused on Innovation + international alignment (G7 Hiroshima)



Australia

- Safe & Responsible AI programme
- Interim government response (2024)
- No single Act yet, but risk-based guidance coming



India

- No omnibus AI law
- MeitY advisories (2024–25)

Why does it matter? LLMs

US	Europe	China	Other
OpenAI → GPT-4, GPT-4o (ChatGPT, Copilot)	Mistral (France) → lightweight open LLMs	Baidu → ERNIE Bot	Cohere (Canada) → enterprise LLMs
Anthropic → Claude models	Aleph Alpha (Germany) → Luminous	Alibaba → Tongyi Qianwen	xAI (US) → Grok
Google DeepMind → Gemini		Huawei / iFlyTek / SenseTime → sector models	Stability AI (UK/US) → Stable Diffusion (images)
Meta → LLaMA family (open source)			MidJourney (US) → image generation

UK

AI

ROYAL PHARMACEUTICAL SOCIETY

RecognitionKnowledgeDevelopmentPrescribingInsurance

SearchLoginJoin usContact usMore

Home > Recognition > All Our Campaigns > Policy A-Z > AI

Artificial Intelligence (AI) in Pharmacy

Contents

- 1 Recommendations
- 2 Introduction
- 3 Scope for AI in pharmacy practice
- 4 Considerations for AI in pharmacy practice
 - Development and Collaboration



2023 AI White Paper

2024 Gov Response 5 principles

2024-25 AI Regulation Bill Draft in Lords

Regulators MHRA AIs as devices

Regulators ICO GDPR, minimisation, explainability

NHS 2025 AI & IG Guidance

NICE AI & Digital Regulations Service

Caldicott Principles apply

Department for Science, Innovation & Technology

Consultation outcome

A pro-innovation approach to AI regulation: government response

Updated 6 February 2024

NIHR Innovation Observatory

Newcastle University

A Horizon Scan of Algorithms Used in the Development of Artificial Intelligence (AI)-Enabled Healthcare Technologies

Authors: Imogen Forsythe, Elizabeth Green, Olushola Ewedairo, Andrew Mkwashi

Date: July 2024



Impact of AI on the regulation of medical products

Implementing the AI White Paper principles

Published April 2024



Policy paper

New approach to ensure regulators and regulation support growth (HTML)

Updated 31 March 2025

GMP - EMA Reflection Paper on AI in Drug Lifecycle

[Reflection paper](#) issued by EMA on use of Artificial Intelligence (AI) in the medicinal product lifecycle Sent 2024.

Manufacturing Considerations:

Model Development & Assessment:

Follow quality risk management principles

Consider ICH Q8, Q9, and Q10 principles.

Revisions to current GMPs are anticipated.

Responsibility:

Marketing authorization holders must ensure compliance with GxP standards.

Early regulatory interaction and scientific advice recommended if AI impacts drug benefit-risk balance.

Practical Applications & Regulatory Challenges:

EMA meeting:

Explored AI and digital technology applications in drug manufacturing.

Discussed regulatory challenges and solutions for AI and ML in production settings.

Emphasized aligning AI applications with current and evolving GMP standards.

The use of Artificial Intelligence (AI) in the medicinal product lifecycle

Share

The reflection paper on the use of artificial intelligence in the lifecycle of medicines outlines the current thinking on the use of artificial intelligence (AI) to support the safe and effective development, regulation and use of human and veterinary medicines.

Human

Scientific guidelines

Page contents

Current version

Document history

This paper reflects on principles relevant to the application of AI and machine learning (ML) at any step of a medicines' lifecycle, from drug discovery to the post-authorisation setting.

Keywords: artificial intelligence, AI, machine learning, ML, regulatory, medicine, human medicinal product, veterinary medicinal product

EU GMP

Document / Annex	What's Changing	Implications (for Pharma / NHS / GMP Teams)
Annex 11 (Computerised Systems – revision)	Tighter requirements for lifecycle management, risk assessment, supplier qualification, audit trails, e-signatures, data integrity.	More rigorous supplier oversight; stronger validation of computerised systems; audit readiness will focus on data integrity and system lifecycle evidence.
Chapter 4 (Documentation – revision)	Documentation expanded beyond paper → must cover hybrid, digital, image, audio, video. Stronger links to risk management and electronic records.	Teams need to manage diverse formats (not just paper/PDF). Expect inspectors to check governance of digital records, metadata, and long-term accessibility.
Annex 22 (NEW – Artificial Intelligence)	Guidance for use of AI/ML in GMP systems. Covers validation, oversight, human review, and risk to product quality/patient safety.	Any AI tool that touches GMP decisions (e.g., batch release support, deviation triage) will need validation and human oversight. Use of “black box” AI will be questioned by regulators.

Part I EU GMP, Annex 15, Annex 16, PIC/S P1011
ICH Guidelines - ICH Q8, ICH Q9, ICH Q10

Example responses to consultation

Annex
22

Comment (only one topic per comment) (max 600 characters)	Rationale (must be included when proposing a change) (max 600 characters)	Proposed wording (must be included when proposing a change) (max 600 characters)
Include validation of data sources and acquisition context in the intended use description.	The Qualified Person must ensure not only data variability but also that data comes from verified and trusted sources to support GMP batch decisions.	<i>This should include a comprehensive characterisation of the data the model is intended to use as input, <u>including its source systems, acquisition methods</u> and all common and rare variations within the sample space.</i>
Add requirement to assess potential model bias in test plans.	Bias detection is a core requirement under the EU AI Act and will help identify model risks early in the validation lifecycle.	<i>The <u>test plan</u> should also include a <u>bias impact assessment where input data includes operator , equipment,process-drift or site-specific attributes.</u></i>

Annex

Comment (only one topic per comment) (max 600 characters)	Rationale (must be included when proposing a change) (max 600 characters)	Proposed wording (must be included when proposing a change) (max 600 characters)
Align wording with Annex 22/EU AI Act principles regarding transparency and human oversight	To future-proof the guidance, references to model transparency, explainability and human-in-the-loop decision-making should be embedded, particularly during lifecycle updates.	<i>'In systems incorporating AI, <u>organisational</u> should ensure that <u>transparency, human oversight and explainability are maintained throughout the lifecycle, and in accordance with Annex 22 Guidance.</u></i>
Define responsibilities for reviewing AI system updates (e.g., model drift or retraining)	There is no mention of roles responsible for monitoring AI system changes, which is critical for sustained GMP compliance and ensuring proper oversight by qualified personnel.	<i><u>Periodic review of system requirements should include inputs from qualified personnel including QP, QA, and AI system owners to assess impact of AI model updates or drifts on GMP compliance.</u></i>

Ch
4

Comment (only one topic per comment) (max 600 characters)	Rationale (must be included when proposing a change) (max 600 characters)	Proposed wording (must be included when proposing a change) (max 600 characters)
Explicitly define how risk-based approaches apply to AI-enabled documentation systems	Risk controls will vary depending on whether AI is involved in decision-making, review or data summarisation.	<i><u>Risk-based approaches should also account for whether AI systems are used in data interpretation, generation, or validation processes."</u></i>
Lifecycle controls should consider AI model lifecycle, not just data.	AI/ML systems evolve over time, requiring traceability not only for data but also for model training, retraining and deployment steps.	<i><u>Controls should ensure traceability and integrity across both data and AI model lifecycles, including training data, model versions and algorithm changes.</u></i>

Regulatory Landscape-FDA

FDA's Interaction with AI	Details
Historic Regulation	FDA has a historical track record of regulating AI largely in the context of medical devices, commonly featuring static algorithms.
Submissions	Over 300 submissions for drugs/biological products with AI components have been reviewed by FDA. (Source: Robert M. Califf, M.D., FDA Commissioner)
Approvals	The FDA has granted approval, clearance, or authorization for more than 880 AI/ML-enabled devices. (Source: FDA webpage)
Recognized Benefits	AI is acknowledged by FDA for its potential in improving product quality, reducing manufacturing defects, and mitigating drug shortages by addressing quality issues.
Current Challenges	Regulating generative AI, owing to its relatively recent emergence, poses a modern regulatory challenge for the FDA.

FDA Discussion Papers

Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products

Background and Scope: The FDA’s Center for Drug Evaluation and Research (CDER) discusses the use of AI/ML in drug development to enhance safety and innovation.

Current Uses of AI/ML: AI/ML is applied in drug discovery, nonclinical and clinical research, postmarket safety surveillance, and advanced pharmaceutical manufacturing.

Considerations: The document outlines standards and practices for AI/ML use, addressing concerns like bias, data integrity, and transparency1.

Next Steps: FDA seeks feedback and collaboration with stakeholders to refine the regulatory landscape for AI/ML in drug development.

Artificial Intelligence in Drug Manufacturing

- Purpose:** The paper aims to gather public feedback on the use of AI in drug manufacturing to help develop a future regulatory framework.
- Mission:** CDER’s mission is to ensure that human drugs are safe, effective, and meet quality standards.
- Advanced Manufacturing:** The paper discusses the potential of advanced manufacturing technologies to improve drug production processes.
- Public Feedback:** The FDA seeks input on various areas related to AI technologies in drug manufacturing to inform future regulations.


Garbage In= Garbage Out



What is a prompt?

The queries and commands that you can put into an AI to get a generated response.

To get the best response, it's important to focus on some of the key elements below when phrasing your prompts.



C Clear and straightforward: Eg: I want to summarise the following report

R Relevant – Include context for what you find most relevant Eg: The focus should be on the investigation action discussed, the audience are Quality Professionals

I Instructive – Set guidelines and instructions for the format of the response Eg: Provide an outline of the issue in 5 bullet points.

S Specific- Define your request precisely, including anything not to be covered Eg: Do not add any additional information only that which is included in the content

P Persona – Assign a role or characteristic Eg: You are a GXP Quality Professional

Copilot- General

How Copilot Helps in Microsoft 365



Meeting Management

What Copilot Does:

Auto-generates meeting summaries and suggests actions

Key Benefits:

- Quickly catch up on missed meetings
- Clear next steps and owners
- Fewer redundant meetings



Email & Scheduling

What Copilot Does:

Summarizes email threads, drafts agendas and replies, schedules meetings with click

Key Benefits:

- Saves multiple manual steps
- Faster agenda creation and responses
- Streamlined scheduling



Information Retrieval

What Copilot Does:

Extracts and summarizes key points from long emails and chat conversations

Key Benefits:

- Faster context gathering
- Highlights decisions, risks, and asks



Overcoming Creative Blocks

What Copilot Does:

Rephrases and clarifies ideas; suggests alternative tones

Key Benefits:

- Improves clarity and communication
- Eases drafting and editing

CoPilot/GPT for Regulatory Summary

AI can quickly summarise regulatory updates (e.g. EU GMP Annex 1). But how reliable is it?



Benefits of AI



Fast first draft



Spot themes and trends



Saves time on background reading

Critical Thinking Using ALCOA+:



Accurate AI may hallucinate or fabricate. Cross-check with validated sources.



Contemporaneous AI's training data may be out of date. Regulations change.



Attributable AI often provides no citations. Can you trace the source?



Cross-check directly with the verified source (e.g. EU GMP Annex 1).

AI can inform - but only human-in-the-loop can verify

Copilot

Here's a concise summary of the most recent updates to EU GMP Annex 1, based on the latest guidance from the European Medicines Agency (EMA):

EU GMP Annex 1 – Key Updates (Effective August 2023)

Purpose of the Update:

To modernize and harmonize requirements for the manufacture of sterile medicinal products, incorporating current best practices, risk-based approaches, and technological advancements.

Key Changes:

1. Contamination Control Strategy (CCS)

- A formal, documented CCS is now required.
- It must integrate Quality Risk Management (QRM) and be maintained throughout the product lifecycle.

2. Enhanced Focus on Pharmaceutical Quality System (PQS)


- Emphasis on ICH Q9 (risk management) and ICH Q10 (quality systems).

CoPilot/GPT for SOP Drafting

AI in SOP Drafting: Apply ALCOA+ Thinking

Scenario

AI drafts a new local SOP for cleaning validation based on user prompts.



Critical Thinking Using ALCOA+



Accurate
No reference to EMA or FDA guidance.



Mimics existing SOPs but lacks formatting for version control and metadata.



Complete
Mimics existing SOPs but lacks formatting for version control and metadata.



Legible
Language is clear but lacks regulatory terminology.



Use AI as a starting point, then validate with SMEs and SOPs.



AI can assist but only human can ensure compliance.

Gen AI Examples

Deviations

Feature 1 — Proofreading (Deviation Module): Checks compliance to SOP-; highlights missing requirements; enforces data consistency; validates Description (5 Whys + 2 Hs), material/batch, dates, escalations.

Feature 2 — RCA Tools & Summary (Deviation Module): Builds sequence of events; supports 5 Whys & 6Ms analysis; produces deviation and executive summaries for clear decisions.

- SOPie: Chat bot for SOPs
- Complaints close out letter
- Quality Insights Portal



Disclaimer


The content in this window was created by Generative AI and serves as a job aid. Be aware that you are responsible for the final content of your record and the execution of any procedurally mandated review steps



Outside of Quality

AI in Drug Discovery & Pharma


AI-Driven Drug Discovery



In Silico Clinical Trials



Federated Learning for Data Sharing



Personalized Medicine



Drug Repurposing Acceleration




Predictive Trial Design



Explainable AI (XAI)



Integration of Wet & Dry Labs



Ethical & Regulatory Evolution



Screening and diagnosis –NHS Cloud

World-first AI system –NHS Patient Safety Concerns

Prescribing Practices


What is Critical Thinking



The objective, systematic, and rational analysis and evaluation of factual evidence in order to form a judgement on a subject, issue, etc...

Critical thinking is our human edge in an AI world

- ❑ Understanding & Evaluating Arguments
- ❑ Awareness of Cognitive Biases



Constant Noise & Speed

Urgent emails. Real-time data. Instant messages
→ **Distraction is the norm**

Decisions Under Pressure

Risk being shaped by bias & emotion
→ **Reflection is often skipped**

Complex Challenges

Unprecedented times go beyond experience or intuition
→ **They demand deeper thinking**

AI: A Double-Edged Tool

Powerful but can be flawed
→ **Unchecked flawed AI data leads to flawed decisions**

The Two Minds of Critical Thinking



Daniel Kahneman's "Thinking, Fast and Slow"

Fast Thinking (System 1)

- Automatic, unconscious, effortless. Rooted in basal ganglia

Examples: Speaking your native language, recognizing faces, reacting instinctively

- Strengths: Speed, efficiency, pattern recognition
- Weaknesses: Prone to biases, errors, and emotional reasoning

 Key Insight:

Automatic thinking is not just simple repetition

It's powerful and capable of learning nuanced, complex patterns-like our spoken language, without our conscious awareness.

The Two Minds of Critical Thinking



Daniel Kahneman's "Thinking, Fast and Slow"

Slow Thinking (System 2)

- Deliberate, conscious, effortful. Tied to the hippocampus/prefrontal cortex

Examples: Used for reasoning, problem-solving, planning, and self-control

- Strengths: Analytical and logical thought
- Weaknesses: Slower, mentally taxing, limited capacity

What thinking habits do you rely on most?"

"Have you ever regretted a fast decision?"

"When was the last time AI helped/hindered your thinking?"

Power lies in observation



But beliefs are hard to change

- ❑ Beliefs resist change due to dopamine rewards from confirming info.
- ❑ Confirmation bias: we seek trust in supportive evidence; contradicting facts feel unrewarding.
- ❑ Changing beliefs requires effort; the brain prefers cognitive ease and consistency.
- ❑ Use AI to challenge assumptions: Devil's Advocate, reflective partner, "rubber duck."

Think Critically

Building Quality Through Mindset + Tools

Mindset

Stay Curious



Practise intellectual humility.
Keep an open mind and
question assumptions.

Question Assumptions

- Seek Challenge
- Be Open to Change

Collaboration



Leverage Team Diversity

Invite different
perspectives to
strengthen
decisions.

Methods & Tools



6W+H
(Who, What,
When, Where,
Why, How)



ALCOA+
(data integrity
check)



Ask thought
questions



Evaluate
evidence
critically

C Challenge
assumptions

L Listen to
viewpoints



E Evaluate
critically



A Ask
questions



R Reflect
before
deciding



**Looks can be deceiving:
Always verify AI**

Utilising AI: Strategies for Success

Evaluate Proficiencies and Constraints

- Analyse the strengths and weaknesses of AI and human capabilities.

Strategic Task Assignment

- Delegate tasks based on whether humans or AI are better suited, optimising efficiency.

Human-AI Collaboration

- Implement AI as a tool to augment human efforts, fostering a synergistic approach.



Take responsibility for your own education

Why this matters



Empathy & compassion

- • Judgment & wisdom
- • Creativity & imagination
- • Ethics & values
- • Human connection & dignity

AI can't replace this — but it can help us protect it.